NO304990B1 - Polypeptid omfattende HCV, NANBV, antigen determinant, fusjonsprotein, immunoanalyse, NANBV diagnostikk, immunoanalysesett og antistoffsammensetning - Google Patents

Polypeptid omfattende HCV, NANBV, antigen determinant, fusjonsprotein, immunoanalyse, NANBV diagnostikk, immunoanalysesett og antistoffsammensetning Download PDF

Info

Publication number
NO304990B1
NO304990B1 NO892931A NO892931A NO304990B1 NO 304990 B1 NO304990 B1 NO 304990B1 NO 892931 A NO892931 A NO 892931A NO 892931 A NO892931 A NO 892931A NO 304990 B1 NO304990 B1 NO 304990B1
Authority
NO
Norway
Prior art keywords
hcv
sequence
polypeptide
antibody
clone
Prior art date
Application number
NO892931A
Other languages
English (en)
Norwegian (no)
Other versions
NO892931L (no
NO892931D0 (no
Inventor
Michael Houghton
Qui-Lim Choo
George Kuo
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27557988&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO304990(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of NO892931D0 publication Critical patent/NO892931D0/no
Publication of NO892931L publication Critical patent/NO892931L/no
Priority to NO955101A priority Critical patent/NO306511B1/no
Priority to NO955102A priority patent/NO303879B1/no
Publication of NO304990B1 publication Critical patent/NO304990B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10Cells modified by introduction of foreign genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • C12Q1/706Specific hybridization probes for hepatitis
    • C12Q1/707Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24211Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
NO892931A 1987-11-18 1989-07-17 Polypeptid omfattende HCV, NANBV, antigen determinant, fusjonsprotein, immunoanalyse, NANBV diagnostikk, immunoanalysesett og antistoffsammensetning NO304990B1 (no)

Priority Applications (2)

Application Number Priority Date Filing Date Title
NO955101A NO306511B1 (no) 1987-11-18 1995-12-15 Rekombinant vektor som selektivt hybridiserer til genomet av hepatitt C-virus (HCV), en vertscelle som er transformert med vektoren, og en fremgangsmaate for aa fremstille et terapeutisk aktivt polypeptid
NO955102A NO303879B1 (no) 1987-11-18 1995-12-15 HCV polynukleotider og anvendelse av disse som primære i en polymerasekjedereaksjon

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US12271487A 1987-11-18 1987-11-18
US13988687A 1987-12-30 1987-12-30
US16107288A 1988-02-26 1988-02-26
US19126388A 1988-05-06 1988-05-06
US26358488A 1988-10-26 1988-10-26
US27145088A 1988-11-14 1988-11-14
PCT/US1988/004125 WO1989004669A1 (en) 1987-11-18 1988-11-18 Nanbv diagnostics and vaccines

Publications (3)

Publication Number Publication Date
NO892931D0 NO892931D0 (no) 1989-07-17
NO892931L NO892931L (no) 1989-09-13
NO304990B1 true NO304990B1 (no) 1999-03-15

Family

ID=27557988

Family Applications (1)

Application Number Title Priority Date Filing Date
NO892931A NO304990B1 (no) 1987-11-18 1989-07-17 Polypeptid omfattende HCV, NANBV, antigen determinant, fusjonsprotein, immunoanalyse, NANBV diagnostikk, immunoanalysesett og antistoffsammensetning

Country Status (18)

Country Link
EP (1) EP0318216B2 (de)
JP (16) JPH02500880A (de)
KR (2) KR0138776B1 (de)
CN (5) CN1074422C (de)
BR (1) BR8807310A (de)
CA (1) CA1341629C (de)
DE (2) DE318216T1 (de)
ES (1) ES2012739T5 (de)
FI (3) FI105652B (de)
GR (1) GR900300069T1 (de)
HK (1) HK38293A (de)
HU (3) HU216017B (de)
IE (1) IE62868B1 (de)
LV (1) LV10726B (de)
NO (1) NO304990B1 (de)
NZ (1) NZ227011A (de)
UA (1) UA42668C2 (de)
WO (1) WO1989004669A1 (de)

Families Citing this family (260)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227011A (en) * 1987-11-18 1992-03-26 Chiron Corp Non-a, non-b-hepatitis (hepatitis c) antigens, proteins, nucleotide sequences, vaccines and kits
US6861212B1 (en) 1987-11-18 2005-03-01 Chiron Corporation NANBV diagnostics and vaccines
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US6171782B1 (en) 1987-11-18 2001-01-09 Chiron Corporation Antibody compositions to HCV and uses thereof
US5698390A (en) * 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
US5350671A (en) * 1987-11-18 1994-09-27 Chiron Corporation HCV immunoassays employing C domain antigens
US5712088A (en) * 1987-11-18 1998-01-27 Chiron Corporation Methods for detecting Hepatitis C virus using polynucleotides specific for same
US5714596A (en) * 1987-11-18 1998-02-03 Chiron Corporation NANBV diagnostics: polynucleotides useful for screening for hepatitis C virus
AU650038B2 (en) * 1988-03-11 1994-06-09 Abbott Laboratories CKS method of protein synthesis
JP2696116B2 (ja) * 1988-09-30 1998-01-14 財団法人阪大微生物病研究会 非a非b肝炎患者の血清と抗原抗体反応するペプチド、及び該ペプチドをコードするdna
US5191064A (en) * 1988-09-30 1993-03-02 The Research Foundation For Microbial Diseases (Osaka University) Non-a, non-b hepatitis virus antigen peptide
JPH02167081A (ja) * 1988-12-21 1990-06-27 Tetsuo Nakamura 非A非B型肝炎ウイルスゲノムRNA、cDNAおよびウイルス抗原蛋白質
KR0185373B1 (ko) * 1989-03-17 1999-05-01 로버트 피. 블랙버언 Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
US6027729A (en) * 1989-04-20 2000-02-22 Chiron Corporation NANBV Diagnostics and vaccines
DK0398748T3 (da) * 1989-05-18 2002-03-18 Chiron Corp NANBV-diagnostika: polynukleotider anvendelige til screening for hepatitis C virus
JPH0330676A (ja) * 1989-06-28 1991-02-08 Sanwa Kagaku Kenkyusho Co Ltd 非a非b型肝炎ウイルスのdna、そのクローン及びこれらの調製法
EP0416725A3 (en) * 1989-07-14 1991-03-20 Chugai Seiyaku Kabushiki Kaisha Blood-borne non-a, non-b hepatitis specific protein, dna encoding it, and process for its production
EP0414475B1 (de) * 1989-08-25 1997-12-10 Chiron Corporation Verfahren zur HCV-Züchtung in Zell-Linien aus B- oder T-Lymphozyten
US5372928A (en) * 1989-09-15 1994-12-13 Chiron Corporation Hepatitis C virus isolates
WO1991004262A1 (en) 1989-09-15 1991-04-04 National Institute Of Health Of Japan New hcv isolates
FR2654113A1 (fr) * 1989-11-09 1991-05-10 Pasteur Institut Procede de diagnostic de virus appartenant a la famille des flaviviridae.
BE1005485A5 (fr) * 1989-12-18 1993-08-10 Wellcome Found Agent viral.
US7166287B1 (en) 1989-12-18 2007-01-23 Glaxo Wellcome Inc. Viral agent
CA2032907C (en) * 1989-12-22 2002-05-14 Richard R. Lesniewski Hepatitis c assay
US5308750A (en) * 1989-12-22 1994-05-03 Abbott Laboratories Monoclonal antibodies to putative HCV E2/NS1 proteins and methods for using same
EP0435229A1 (de) * 1989-12-27 1991-07-03 Sanwa Kagaku Kenkyusho Co., Ltd. DNS-Gen von einem Non-A Non-B Hepatitis-Virus, seine Klonierung und Verwendung
DK0441644T3 (de) * 1990-02-09 1997-03-03 Japan Immuno Inc
US5106726A (en) * 1990-02-16 1992-04-21 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
KR940000755B1 (ko) * 1990-02-16 1994-01-29 유나이티드 바이오메디칼 인코오포레이티드 Hcv에 대한 항체 검출, hcv 감염의 진단 및 백신으로서의 그 예방에 특히 적합한 합성 펩티드
US5582968A (en) * 1990-02-16 1996-12-10 United Biomedical, Inc. Branched hybrid and cluster peptides effective in diagnosing and detecting non-A, non-B hepatitis
US5639594A (en) * 1990-02-16 1997-06-17 United Biomedical, Inc. Linear and branched peptides effective in diagnosing and detecting non-A, non-B hepatitis
EP0445801A3 (en) * 1990-03-08 1992-07-01 Kuraray Co., Ltd. Peptide and its use
EP0447984A1 (de) * 1990-03-20 1991-09-25 Abbott Laboratories Hyperimmunglobulin gegen Hepatitis-C-Virus und Verfahren zur Herstellung
JPH0436185A (ja) * 1990-03-28 1992-02-06 Kyowa Hakko Kogyo Co Ltd 融合抗原ポリペプチド
WO1991014779A1 (fr) * 1990-03-28 1991-10-03 Mitsui Toatsu Chemicals, Incorporated Diagnostic du virus de l'hepatite
HU217025B (hu) * 1990-04-04 1999-11-29 Chiron Corp. Hepatitis C vírus-(HCV) antigénkészítmények az anti-HCV-antitestek kimutatására immunoassay-kben
US6312889B1 (en) 1990-04-04 2001-11-06 Chiron Corporation Combinations of hepatitis c virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
ATE270326T1 (de) * 1990-04-04 2004-07-15 Chiron Corp Protease von hepatitis-c-virus
US6194140B1 (en) * 1990-04-04 2001-02-27 Chiron Corporation HCV NS3 protein fragments having helicase activity and improved solubility
CA2079912C (en) * 1990-04-06 2000-07-11 Gregory Reyes Hepatitis c virus epitopes
CA2044296A1 (en) * 1990-06-12 1991-12-13 Hiroaki Okamoto Oligonucleotide primers, and their application for high-fidelity detection of non-a, non-b hepatitis virus
JP3050395B2 (ja) * 1990-06-12 2000-06-12 国立感染症研究所長 C型肝炎ウイルス抗原ポリペプチド、その産生方法および抗体の検出方法
EP0464287A1 (de) * 1990-06-25 1992-01-08 The Research Foundation for Microbial Diseases of Osaka University Non-A, Non-B Hepatitis Virus genomisches DNS und Antigenpolypeptide
US5747339A (en) * 1990-06-25 1998-05-05 Research Foundation For Microbial Diseases Of Osaka Non-A, non-B hepatitis virus genomic CDNA and antigen polypeptide
FI913068L (fi) * 1990-06-25 1991-12-26 Univ Osaka Res Found Non-a-, non-b-hepatitisviruspartiklar.
WO1992000328A1 (en) * 1990-06-30 1992-01-09 Akzo N.V. Non-a non-b sequences
KR0181517B1 (ko) * 1990-07-09 1999-04-01 나까하라 노부유끼 비-에이 비-비형 간염-특이 항원 및 간염 진단에서 그의 용도
EP0469348B1 (de) * 1990-07-11 1997-03-12 SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. cDNS-Sequenz und Detektion des Hepatitis C-Virus
WO1992001714A1 (fr) * 1990-07-24 1992-02-06 Yamanouchi Pharmaceutical Co., Ltd. Antigene du virus de l'hepatite non a, non b
CA2047792C (en) * 1990-07-26 2002-07-02 Chang Y. Wang Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines
CZ282573B6 (cs) * 1990-08-10 1997-08-13 Chiron Corporation Způsob detekce HCV sekvence, souprava a reakční činidlo pro detekci HCV
CA2049679C (en) * 1990-08-24 2005-06-21 Sushil G. Devare Hepatitis c assay utilizing recombinant antigens
US6172189B1 (en) * 1990-08-24 2001-01-09 Abbott Laboratories Hepatitis C assay utilizing recombinant antigens
ATE346302T1 (de) * 1990-08-25 2006-12-15 Bioprocess Pty Ltd Nicht-a, nicht-b hepatitis virus antigen, und diagnostische verfahren.
US7863008B2 (en) 1990-08-25 2011-01-04 Bioprocess Pty Ltd. Method for detecting NANBV associated seroconversion
EP0552297A1 (de) * 1990-10-12 1993-07-28 Abbott Laboratories Antikörper gegen hepatitis-c antigene
JP3549201B2 (ja) * 1990-10-24 2004-08-04 中外製薬株式会社 非a非b型肝炎特異的遺伝子の検出方法及び検出用試薬組成物
DE4034982C2 (de) * 1990-11-03 1999-12-23 Dade Behring Marburg Gmbh Synthetische Polypeptide zur Bestimmung von HCV-Antikörpern und HCV-Antigenen, Mittel dazu und ihre Verwendung in diesen Nachweis-Verfahren
DE4121431A1 (de) * 1991-06-28 1993-01-07 Behringwerke Ag Synthetische core-peptide zur bestimmung von hcv-antikoerpern und hcv-antigenen, mittel dazu und ihre verwendung in diesen nachweis-verfahren
ATE206717T1 (de) * 1990-11-03 2001-10-15 Dade Behring Marburg Gmbh Hcv-spezifische peptide, mittel dazu und ihre verwendung
DE4120281C2 (de) * 1991-06-19 1999-11-25 Dade Behring Marburg Gmbh Immunchemisches Verfahren zum gleichzeitigen Nachweis von mehreren verschiedenen Antikörperspezifitäten, Peptidmischungen und Test dazu
DE4112743C2 (de) * 1991-04-19 2000-01-13 Dade Behring Marburg Gmbh Synthetische Core-Peptide zur Bestimmung von HCV-Antikörpern und HCV-Antigenen, Mittel dazu und ihre Verwendung in diesen Nachweis-Verfahren
US5753430A (en) * 1990-11-07 1998-05-19 Abbott Laboratories Monoclonal antibodies to hepatitis C virus and method for using same
AU662503B2 (en) * 1990-11-07 1995-09-07 Abbott Laboratories Monoclonal antibodies to hepatitis C virus and method for using same
EP0842947B2 (de) * 1990-11-08 2009-03-18 Novartis Vaccines and Diagnostics, Inc. Asialoglykoproteine des Hepatitis C Virus
US6274148B1 (en) * 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
CA2055149A1 (en) * 1990-11-08 1992-05-09 Hiroaki Okamoto Non-a, non-b hepatitis virus related antigen, antibody, detection systems, polynucleotides and polypeptides
KR920703640A (ko) * 1990-11-29 1992-12-18 테루카츄 아리마 비a비b형 간염 바이러스 항원 단백질
EP0488812B1 (de) * 1990-11-30 1999-06-09 Immuno Japan Inc. Non-A, non-B hepatitisverwandte Nukleinsäuren, Antigene und Antikörper und ihre Feststellungsreagenzien
US6007982A (en) * 1990-12-14 1999-12-28 Innogenetics N.V. Synthetic antigens for the detection of antibodies to hepatitis C virus
US5910404A (en) 1990-12-14 1999-06-08 Innogenetics N.V. Synthetic antigens for the detection of antibodies to hepatitis C virus
EP0754704B1 (de) * 1990-12-14 1999-10-06 Innogenetics N.V. Synthetische Antigene zum Nachweis von Antikörpern gegen Hepatitis C Virus
CA2101056A1 (en) * 1991-01-25 1992-07-26 Adrienne L. Gilbert Use of superoxide dismutase in specimen diluent
ATE167522T1 (de) * 1991-01-31 1998-07-15 Abbott Lab Monoklonale antikörper gegen mögliche hcv- hüllregionen und methoden diese zu benutzen
ES2098511T3 (es) * 1991-03-26 1997-05-01 Dade Int Inc Procedimiento de diagnosis de hepatitis no-a no-b.
US5574132A (en) * 1991-04-05 1996-11-12 Biochem Immunosystems Inc. Peptides and mixtures thereof for detecting antibodies to hepatitis C virus (HCV)
EP0516270A3 (en) * 1991-04-10 1993-06-23 Immuno Japan Inc. Non-a, non-b hepatitis virus related antigen, antibody, detection systems, polynucleotides and polypeptides
WO1992018532A1 (fr) * 1991-04-17 1992-10-29 Eisai Co., Ltd. Arn, adn et proteine antigenique virale du virus de l'hepatite non-a, non-b
EP0510952A1 (de) * 1991-04-26 1992-10-28 Immuno Japan Inc. Oligonukleotid-Primer und ihre Anwendung zum Nachweis von Non-A, Non-B-Hepatitis mit höchster Genauigkeit
SK284205B6 (sk) * 1991-05-08 2004-10-05 Chiron Corporation Prirodzene sa nevyskytujúca nukleová kyselina, spôsob tvorby hybridizačného produktu a spôsob detekcie genotypov HCV
ES2040615B1 (es) * 1991-05-27 1994-05-16 Nebrda Fernando Javi Bartolome Procedimiento para el aislamiento y clonaje de cdnas derivados del virus c de la hepatitis.
FR2677372B1 (fr) * 1991-06-06 1994-11-10 Pasteur Institut Sequences nucleotidiques et peptidiques d'un isolat de virus de l'hepatite c, applications diagnostiques et therapeutiques.
JPH06508024A (ja) * 1991-06-10 1994-09-14 ラッキー・リミテッド C型肝炎診断試薬およびワクチン
CA2070952A1 (en) * 1991-06-11 1992-12-12 Makoto Seki Gene of hepatitis c virus or fragment thereof, polypeptide encoded by the same
WO1993000365A2 (en) * 1991-06-24 1993-01-07 Chiron Corporation Hepatitis c virus (hcv) polypeptides
DE4209215A1 (de) 1991-07-04 1993-01-07 Boehringer Mannheim Gmbh Hcv peptidantigene und verfahren zur bestimmung von hcv
JPH06510289A (ja) * 1991-08-21 1994-11-17 アボツト・ラボラトリーズ Ns5領域由来の組換え抗原を利用したc型肝炎アッセイ
JPH06510188A (ja) * 1991-08-21 1994-11-17 アボツト・ラボラトリーズ 推定hcv ns5タンパクに対するモノクローナル抗体およびそれを使用する方法
AU2513592A (en) * 1991-08-21 1993-03-16 Abbott Laboratories Hepatitis c assay utilizing recombinant antigens to ns1
ATE161291T1 (de) * 1991-08-27 1998-01-15 Hoffmann La Roche Verfahren und reagenzien zum nachweis von hepatitis c
WO1993006126A1 (en) * 1991-09-13 1993-04-01 Chiron Corporation Immunoreactive hepatitis c virus polypeptide compositions
ZA927837B (en) * 1991-10-15 1994-03-11 Akzo Nv Monoclonal antibodiesto hepatitis C virus
CA2099883A1 (en) * 1991-11-07 1993-05-08 John A. Kink Epitope mapping of the c33c region of hcv
JPH05130874A (ja) * 1991-11-07 1993-05-28 Sanwa Kagaku Kenkyusho Co Ltd ヒトC型肝炎ウイルスのcDNA、そのクローン及びこれらの利用法
DE69232906T2 (de) 1991-11-21 2004-01-15 Common Services Agency Edinbur Detektion des Hepatis-C Virus.
EP0627000B1 (de) * 1992-01-31 2003-10-29 Abbott Laboratories Expressionssystem in säugetieren für hcv-proteine
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
MA22842A1 (fr) * 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
US5866139A (en) * 1992-06-04 1999-02-02 Institut Pasteur Nucleotide and peptide sequences of a hepatitis C virus isolate, diagnostic and therapeutic applications
US5980899A (en) * 1992-06-10 1999-11-09 The United States Of America As Represented By The Department Of Health And Human Services Identification of peptides that stimulate hepatitis C virus specific cytotoxic T cells
UA39944C2 (uk) 1992-07-07 2001-07-16 Чірон Корпорейшн Спосіб визначення ранньої сероконверсії у ссавця-хазяїна до вірусу гепатиту с і набір для використання в способі
US5859230A (en) * 1992-07-30 1999-01-12 Genelabs Technologies, Inc. Non-A/non-B/non-C/non-D/non-E hepatitis agents and molecular cloning thereof
DE4240980A1 (de) * 1992-08-07 1994-02-10 Boehringer Mannheim Gmbh HCV Peptidantigene und Verfahren zur Bestimmung von HCV
US6174868B1 (en) 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US6995146B2 (en) 1992-09-10 2006-02-07 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US6391542B1 (en) 1992-09-10 2002-05-21 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus-associated diseases
CA2143678A1 (en) 1992-09-10 1994-03-17 Kevin P. Anderson Compositions and methods for treatment of hepatitis c virus-associated diseases
US6433159B1 (en) 1992-09-10 2002-08-13 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus associated diseases
US5922857A (en) 1992-09-28 1999-07-13 Chiron Corporation Methods and compositions for controlling translation of HCV proteins
CN1059928C (zh) * 1992-09-29 2000-12-27 天津普生生物科技有限公司 利用大肠杆菌制备可用来检验c型肝炎之抗原蛋白的方法
JPH06153959A (ja) * 1992-10-16 1994-06-03 Evernew Biotec Inc C型肝炎ウィルスの非構造タンパク質及びそれを用いての診断方法及びキット
US6153378A (en) * 1992-10-16 2000-11-28 Bionova Corporation Diagnosis of, and vaccination against, a positive stranded RNA virus using an isolated, unprocessed polypeptide encoded by a substantially complete genome of such virus
JP2778886B2 (ja) * 1992-10-16 1998-07-23 エバーニュー バイオテック インコーポレイティド C型肝炎ウィルスのコア抗原タンパク質及びそれを用いての診断方法及びキット
EP0593291A3 (de) * 1992-10-16 1995-03-15 Evernew Biotech Inc Nichtstrukturales Protein des Hepatitis C-Virus, sowie diagnostisches Verfahren und Testsatz.
CA2151126A1 (en) * 1992-12-07 1994-06-23 Winand Johannes Antonius Habets Peptides from the c33 region of hcv, antibodies thereto and methods for the detection of hcv
AU6653394A (en) * 1992-12-07 1994-07-04 Akzo Nobel N.V. Hepatitis c virus (hcv) non-structural-3 peptides, antibodies thereto and methods for the detection of hcv
WO1994024565A1 (en) * 1993-04-22 1994-10-27 Genelabs Technologies, Inc. Hepatitis c virus immunodiagnostic antigens and antibodies
EP0651807B1 (de) * 1993-04-27 2007-09-12 N.V. Innogenetics S.A. Sequenzen der genotype des hepatitis-c-virus sowie ihre verwendung als arzneimitteln und diagnostika
ATE281526T1 (de) 1993-05-05 2004-11-15 Common Services Agency Hepatitis-c virus typ 4,5 und 6
PT698216E (pt) 1993-05-10 2005-03-31 Chiron Corp Metodos de tipificacao do virus da hepatite c e reagentes para utilizar nestes
JPH08510240A (ja) 1993-05-12 1996-10-29 カイロン コーポレイション C型肝炎ウイルスe2/ns1領域の保存モチーフ
AU8003894A (en) * 1993-10-29 1995-05-22 Srl Inc. Antigen peptide compound and immunoassay method
US5610009A (en) * 1994-01-28 1997-03-11 Abbott Laboratories Mammalian expression systems for hepatitis C virus envelope genes
US5981172A (en) * 1994-02-14 1999-11-09 Abbott Laboratories Non-A, non-B, non-C, non-D, non-E Hepatitis reagents and methods for their use
US6451578B1 (en) 1994-02-14 2002-09-17 Abbott Laboratories Non-A, non-B, non-C, non-D, non-E hepatitis reagents and methods for their use
US6156495A (en) * 1994-02-14 2000-12-05 Abbott Laboratories Hepatitis GB virus recombinant proteins and uses thereof
US6051374A (en) * 1994-02-14 2000-04-18 Abbott Laboratories Non-A, non-B, non-C, non-D, non-E hepatitis reagents and methods for their use
US6558898B1 (en) 1994-02-14 2003-05-06 Abbott Laboratories Non-A, non-B, non-C, non-D, non-E hepatitis reagents and methods for their use
US5843450A (en) * 1994-02-14 1998-12-01 Abbott Laboratories Hepatitis GB Virus synthetic peptides and uses thereof
US6720166B2 (en) 1994-02-14 2004-04-13 Abbott Laboratories Non-a, non-b, non-c, non-c, non-d, non-e hepatitis reagents and methods for their use
US5824507A (en) * 1994-05-20 1998-10-20 Genelabs Technologies, Inc. Hepatitis G virus and molecular cloning thereof
US5874563A (en) * 1994-05-20 1999-02-23 Genelabs Technologies, Inc. Hepatitis G virus and molecular cloning thereof
JP3217600B2 (ja) 1994-07-12 2001-10-09 株式会社先端生命科学研究所 非a非b型肝炎ウイルス関連抗原のイムノアッセイ、それに使用するモノクローナル抗体、およびこの抗体を産生するハイブリドーマ
AU3241095A (en) * 1994-07-29 1996-03-04 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
EP1510580B1 (de) 1994-07-29 2008-12-10 Novartis Vaccines and Diagnostics, Inc. Hepatitis C E2 verkuerzte Polypeptid sowie Verfahen zu seiner Herstellung
DE4428705A1 (de) 1994-08-12 1996-02-15 Boehringer Mannheim Gmbh Rekombinantes Antigen aus der NS3-Region des Hepatitis C Virus
US5709997A (en) * 1995-08-14 1998-01-20 Abbott Laboratories Nucleic acid detection of hepatitis GB virus
US5955318A (en) * 1995-08-14 1999-09-21 Abbott Laboratories Reagents and methods useful for controlling the translation of hepatitis GBV proteins
US5807670A (en) * 1995-08-14 1998-09-15 Abbott Laboratories Detection of hepatitis GB virus genotypes
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
GB9517926D0 (en) 1995-09-01 1995-11-01 Biocine Spa Binding protein
US5851758A (en) * 1995-10-25 1998-12-22 Childrens Research Institute Cytopathic replication of hepatitis C virus in a new cell line
US5837442A (en) 1995-11-29 1998-11-17 Roche Molecular Systems, Inc. Oligonucleotide primers for amplifying HCV nucleic acid
US5851759A (en) * 1996-04-19 1998-12-22 Chiron Corporation Heteroduplex tracking assay (HTA) for genotyping HCV
JP3715027B2 (ja) 1996-05-07 2005-11-09 シスメックス株式会社 C型肝炎ウイルス感染症診断薬
CU22642A1 (es) * 1996-12-12 2000-12-22 Ct Ingenieria Genetica Biotech Secuencia de adnc derivadas del genoma del virus de la hepatitis c y su uso
US7049428B1 (en) 1998-03-04 2006-05-23 Washington University HCV variants
US7338759B1 (en) 1997-03-04 2008-03-04 Washington University HCV variants
CA2288374A1 (en) 1997-05-06 1998-11-12 Chiron Corporation Intracellular production of hepatitis c e1 and e2 truncated polypeptides
US6010848A (en) * 1997-07-02 2000-01-04 Smithkline Beecham Corporation Screening methods using an atpase protein from hepatitis C virus
US6153392A (en) * 1997-07-30 2000-11-28 Bionova Corporation Devices and methods comprising an HBcAg from hepatitis B virus
JP4198882B2 (ja) 1997-10-06 2008-12-17 カイロン ソチエタ ア レスポンサビリタ リミタータ C型肝炎レセプタータンパク質cd81
CN1263854C (zh) 1997-11-06 2006-07-12 启龙股份公司 奈瑟球菌抗原
US6228576B1 (en) 1997-12-11 2001-05-08 Smithkline Beecham Corporation Hepatitis C virus NS5B truncated protein and methods thereof to identify antiviral compounds
AU1979599A (en) 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
EP2261352A3 (de) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Antigene und Zusammensetzungen gegen Neisseria meningitidis
US8206749B1 (en) 1999-02-26 2012-06-26 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
CA2366688A1 (en) 1999-02-26 2000-08-31 Chiron Corporation Use of bioadhesives and adjuvants for the mucosal delivery of antigens
JP2003518363A (ja) 1999-04-30 2003-06-10 カイロン エセ.ピー.アー. 保存されたナイセリア抗原
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
EP1200109A4 (de) * 1999-07-19 2005-06-15 Epimmune Inc Verwendung von peptid-nukleinsäureverbindungen zur auslösung zellulärer immunantworten gegen hepatitis c
RU2281956C2 (ru) 1999-10-29 2006-08-20 Чирон С.Р.Л. Антигенные пептиды neisseria
US7196066B1 (en) 1999-11-03 2007-03-27 Powderject Vaccines, Inc. DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
JP2004500366A (ja) * 1999-12-01 2004-01-08 カイロン コーポレイション C型肝炎ウイルス(hcv)について特異的な抗体を誘発すること
PT2289545T (pt) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
ES2317900T3 (es) 2000-04-05 2009-05-01 Schering Corporation Inhibidores de serina proteasa ns3 macrociclicos del virus de la hepatitis c que comprenden fragmentos n-ciclicas p2.
AU2001253621A1 (en) 2000-04-19 2001-11-07 Schering Corporation Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties
DK1354204T4 (da) 2000-06-15 2010-06-14 Novartis Vaccines & Diagnostic HCV-antigen/antistof-kombinationssay
EP1829891B1 (de) * 2000-06-15 2012-12-26 Novartis Vaccines and Diagnostics, Inc. Immuntests für Anti-HCV-Antikörper
SK742003A3 (en) 2000-07-21 2003-06-03 Schering Corp Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
CN1498224A (zh) 2000-07-21 2004-05-19 ���鹫˾ 用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
RU2286172C2 (ru) 2000-08-17 2006-10-27 Трипеп Аб Вакцины, содержащие рибавирин, и способы их использования
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
JP5175417B2 (ja) * 2000-08-17 2013-04-03 トリペップ アクチ ボラゲット リバビリンを含むワクチンおよびその使用方法
DK1328543T3 (da) 2000-10-27 2009-11-23 Novartis Vaccines & Diagnostic Nukleinsyrer og proteiner fra streptococcus-gruppe A & B
AU3659102A (en) 2000-12-12 2002-06-24 Schering Corp Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
AU2002303330B2 (en) 2001-05-31 2008-07-24 Novartis Vaccines And Diagnostics, Inc. Chimeric alphavirus replicon particles
US7196183B2 (en) 2001-08-31 2007-03-27 Innogenetics N.V. Hepatitis C virus genotype, and its use as prophylactic, therapeutic and diagnostic agent
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
CN100515494C (zh) 2001-12-12 2009-07-22 启龙有限公司 抗沙眼衣原体的免疫
CN100352819C (zh) 2002-01-23 2007-12-05 先灵公司 作为ns3-丝氨酸蛋白酶抑制剂的脯氨酸化合物用于制备治疗丙型肝炎病毒感染的药物
GB0201679D0 (en) * 2002-01-25 2002-03-13 Asterion Ltd Polypeptide variants
EP2572707A3 (de) 2002-02-20 2013-11-06 Novartis Vaccines and Diagnostics, Inc. Mikropartikel mit adsorbierten polypeptidhaltigen Molekülen
ES2346717T3 (es) 2002-03-11 2010-10-19 Lab 21 Limited Metodo y composiciones para identificar y caracterizar la hepatitis c.
US7598421B2 (en) 2002-05-08 2009-10-06 Ucl Biomedica Plc Materials for the delivery of biologically-active material to cells
AU2003239894A1 (en) 2002-05-24 2003-12-12 Restoragen Inc. Methods and constructs for high yield expression of clostripain
ATE410693T1 (de) 2002-09-09 2008-10-15 Novartis Vaccines & Diagnostic Hcv-test
CA2868618C (en) 2002-10-16 2017-05-23 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
US7927840B2 (en) 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
GB0226722D0 (en) * 2002-11-15 2002-12-24 Glaxo Group Ltd Vaccine
AU2003299994A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Immunogenic compositions containing phospholpid
KR101192652B1 (ko) 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
US7833775B2 (en) 2003-02-06 2010-11-16 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
WO2005021584A2 (en) 2003-08-26 2005-03-10 Schering Corporation Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus
ES2596753T3 (es) 2003-08-29 2017-01-11 Fujirebio Europe N.V. Nuevo clado del virus de la hepatitis C y secuencias prototipo del mismo
EP2062590A1 (de) 2003-09-22 2009-05-27 Green Peptide Co., Ltd. Von Hepatitis-C-Virus abgeleitetes Peptid
JP4525982B2 (ja) 2003-09-26 2010-08-18 シェーリング コーポレイション C型肝炎ウイルスのns3セリンプロテアーゼの大環状インヒビター
HRP20130098T1 (hr) * 2003-10-14 2013-02-28 F. Hoffmann - La Roche Ag MAKROCIKLIÄŚKE KARBOKSILNE KISELINE I ACILSULFONAMIDNI SPOJEVI KAO INHIBITORI REPLIKACIJE HCV-a
JP2007532479A (ja) 2003-11-20 2007-11-15 シェーリング コーポレイション C型肝炎ウイルスns3プロテアーゼの脱ペプチド化インヒビター
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
EP1737881B1 (de) 2004-02-27 2009-06-24 Schering Corporation Neue verbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
WO2005087721A2 (en) 2004-02-27 2005-09-22 Schering Corporation Compounds as inhibitors of hepatitis c virus ns3 serine protease
EP1730165A1 (de) 2004-02-27 2006-12-13 Schering Corporation Inhibitoren der ns3-protease des hepatitis-c-virus
DE602005015834D1 (de) 2004-02-27 2009-09-17 Schering Corp 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
DE602005015452D1 (de) 2004-05-20 2009-08-27 Schering Corp Substituierte proline als hemmer der ns3-serinprotease des hepatits-c-virus
EP1784211A4 (de) 2004-07-29 2010-06-30 Novartis Vaccines & Diagnostic Immunogene zusammensetzungen für grampositive bakterien wie streptococcus agalactiae
ES2377978T3 (es) 2004-08-27 2012-04-03 Novartis Vaccines And Diagnostics, Inc. Mutantes de proteínas no estructurales de VHC y usos de los mismos
CA2577812A1 (en) 2004-08-27 2006-03-09 Schering Corporation Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease
EP1828224B1 (de) 2004-12-22 2016-04-06 Ambrx, Inc. Zusammensetzungen mit, verfahren mit und verwendungen von nichtnatürlichen aminosäuren und polypeptiden
EP1874342B1 (de) 2005-04-26 2018-06-06 Eisai R&D Management Co., Ltd. Zusammensetzungen und verfahren für die krebsimmuntherapie
CA2618429A1 (en) 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
NZ563365A (en) 2005-06-02 2011-02-25 Schering Corp Combination of HCV protease inhibitors with a surfactant
NZ563361A (en) 2005-06-02 2011-02-25 Schering Corp HCV protease inhibitors in combination with food
ES2886923T3 (es) 2005-09-20 2021-12-21 Menarini Silicon Biosystems Spa Métodos y composición para generar sondas de ADN de secuencia única, marcaje de sondas de ADN y el uso de estas sondas
WO2007135707A1 (ja) 2006-05-18 2007-11-29 Nichia Corporation 樹脂成形体及び表面実装型発光装置並びにそれらの製造方法
DK2054431T3 (da) 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
EP2185195A2 (de) 2007-08-16 2010-05-19 Tripep Ab Immunogen-plattform
US20090214593A1 (en) 2007-08-16 2009-08-27 Tripep Ab Immunogen platform
NZ599777A (en) 2007-11-07 2013-09-27 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
EP3067048B1 (de) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Zusammensetzungen zur induzierung von immunreaktionen
NZ586947A (en) 2008-02-08 2012-11-30 Ambrx Inc Modified leptin polypeptides and their uses
CN102076843A (zh) 2008-05-19 2011-05-25 艾杜罗生物科技公司 包含prfa*突变体李斯特菌的组合物及其使用方法
MX2011003272A (es) 2008-09-26 2011-04-28 Ambrx Inc Polipeptidos de eritropoyetina animal modificados y sus usos.
TW201032801A (en) 2008-12-12 2010-09-16 Schering Corp Deuterated compounds as hepatitis C virus (HCV) inhibitors
JP2012519724A (ja) 2009-03-09 2012-08-30 ヘンルイ ウイルリアム シグナルペプチドを担体として有する細菌毒素とのハプテン‐担体抱合体及び免疫原性組成物としてのその使用
CA2763140A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
US20110300205A1 (en) 2009-07-06 2011-12-08 Novartis Ag Self replicating rna molecules and uses thereof
JP2013512246A (ja) 2009-11-25 2013-04-11 メルク・シャープ・アンド・ドーム・コーポレーション ウイルス疾患治療に有用な縮合型三環式化合物およびその誘導体
EP2333074A1 (de) 2009-12-14 2011-06-15 Robert Steinfeld Substanzen und Verfahren zur Behandlung von lyosomalen Speicherkrankheiten
US20130156731A1 (en) 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
KR101781789B1 (ko) 2010-01-27 2017-09-26 에이비 파르마 리미티드. C형 간염 바이러스 억제제로 사용되는 다환 헤테로사이클릭 화합물
EA201290882A1 (ru) 2010-03-09 2013-04-30 Мерк Шарп Энд Домэ Корп. Конденсированные трициклические силильные соединения и способы их применения для лечения вирусных заболеваний
EP3165540A1 (de) 2010-04-13 2017-05-10 Celldex Therapeutics, Inc. Antikörper zur bindung von humanem cd27 und verwendungen davon
EP2590625B1 (de) 2010-07-06 2017-09-20 GlaxoSmithKline Biologicals SA Kationische öl-in-wasser emulsionen
WO2012018534A2 (en) 2010-07-26 2012-02-09 Schering Corporation Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
JP2013540122A (ja) 2010-09-29 2013-10-31 メルク・シャープ・エンド・ドーム・コーポレイション 縮合四環式化合物誘導体およびウィルス疾患治療のためのそれの使用方法
WO2012142075A1 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
BR112013026345A2 (pt) 2011-04-13 2019-04-24 Merck Sharp & Dohe Corp. composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
CA2857705A1 (en) 2011-06-16 2012-12-20 AB Pharma Ltd. Macrocyclic heterocyclic compounds for inhibiting hepatitis c virus and preparation and use thereof
SG10201605512WA (en) 2011-07-06 2016-09-29 Novartis Ag Oil-in-water emulsions that contain nucleic acids
CA2840965C (en) 2011-07-06 2021-03-02 Novartis Ag Cationic oil-in-water emulsions
US20140378416A1 (en) 2011-09-14 2014-12-25 Michael P. Dwyer Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
BR112014008694A2 (pt) 2011-10-11 2017-06-20 Novartis Ag moléculas de ácido nucleico policistrônico recombinante
US20180044429A1 (en) 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
WO2016160046A1 (en) 2015-03-27 2016-10-06 Ortho-Clinical Diagnostics, Inc. Hcv ns4a/modified ns3 polypeptides and uses thereof
US10550379B2 (en) 2015-06-29 2020-02-04 The Board Of Trustees Of The Leland Stanford Junior University Degron fusion constructs and methods for controlling protein production
US12297266B2 (en) 2016-04-18 2025-05-13 Celldex Therapeutics, Inc. Agonistic antibodies that bind human CD40 and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464474A (en) * 1980-07-09 1984-08-07 Connaught Laboratories Limited Non-A, non-B hepatitis assay and vaccine
EP0071640B1 (de) * 1981-02-11 1986-06-04 Connaught Laboratories Incorporated Nicht-a, nicht-b hepatitisvirus
US4702909A (en) * 1982-05-05 1987-10-27 Louisiana State University A & M Non-A, non-B hepatitis antigen, antigen compositions, vaccine and diagnostic reagent
US4673634A (en) * 1985-03-08 1987-06-16 The United States Of America As Represented By The Department Of Health And Human Services Purified antigen from non-A, non-B hepatitis causing factor
AU613310B2 (en) * 1986-04-01 1991-08-01 Genelabs Incorporated Immortalized virus-specific tissue cells
JPS6391328A (ja) * 1986-10-07 1988-04-22 Mitsubishi Kasei Corp 非a非b型肝炎抗原
NZ222465A (en) * 1986-11-07 1992-11-25 Pasteur Institut Nanb (non a, non b hepatitis viral) antigen
DE3744242A1 (de) * 1987-02-20 1989-07-06 Seelig Renate Virusantigen, verfahren zu seiner gewinnung und anwendung in diagnose und therapie (impfstoff)
NZ227011A (en) * 1987-11-18 1992-03-26 Chiron Corp Non-a, non-b-hepatitis (hepatitis c) antigens, proteins, nucleotide sequences, vaccines and kits

Also Published As

Publication number Publication date
HUT53148A (en) 1990-09-28
JPH06128293A (ja) 1994-05-10
EP0318216B2 (de) 2001-08-29
JPH06128291A (ja) 1994-05-10
HU220204B (hu) 2001-11-28
CN1299973A (zh) 2001-06-20
JP2532805B2 (ja) 1996-09-11
HU216017B (hu) 1999-04-28
IE883472L (en) 1989-05-18
JP2007197456A (ja) 2007-08-09
FI105652B (fi) 2000-09-29
HK1026023A1 (en) 2000-12-01
JP2006117681A (ja) 2006-05-11
FI981380A0 (fi) 1988-11-18
JP2008007508A (ja) 2008-01-17
UA42668C2 (uk) 2001-11-15
WO1989004669A1 (en) 1989-06-01
JPH06225797A (ja) 1994-08-16
JPH09184844A (ja) 1997-07-15
KR19980701583A (ko) 1998-05-15
LV10726A (lv) 1995-06-20
KR890701126A (ko) 1989-12-19
JPH10108674A (ja) 1998-04-28
HU9502949D0 (en) 1995-12-28
BR8807310A (pt) 1990-03-13
ES2012739T3 (es) 1994-12-01
NO892931L (no) 1989-09-13
JPH10290696A (ja) 1998-11-04
JP2662350B2 (ja) 1997-10-08
GR900300069T1 (en) 1991-07-31
CA1341629C (en) 2012-05-08
CN1129796C (zh) 2003-12-03
JP2809956B2 (ja) 1998-10-15
FI106564B (fi) 2001-02-28
FI893447A0 (fi) 1989-07-17
EP0318216B1 (de) 1993-12-15
JP2662358B2 (ja) 1997-10-08
HK38293A (en) 1993-04-30
JPH06128290A (ja) 1994-05-10
JPH10290697A (ja) 1998-11-04
CN1074422C (zh) 2001-11-07
JP2662351B2 (ja) 1997-10-08
JP3171793B2 (ja) 2001-06-04
KR0138776B1 (ko) 1998-05-15
JPH09173079A (ja) 1997-07-08
CN1159584C (zh) 2004-07-28
LV10726B (en) 1995-12-20
FI893447A7 (fi) 1989-07-17
DE3886363D1 (de) 1994-01-27
HK1033773A1 (en) 2001-09-21
FI107620B (fi) 2001-09-14
ES2012739A4 (es) 1990-04-16
DE318216T1 (de) 1990-06-13
KR100216013B1 (ko) 1999-08-16
JPH0581600B1 (de) 1993-11-15
JPH02500880A (ja) 1990-03-29
JP2000023683A (ja) 2000-01-25
JP2006104207A (ja) 2006-04-20
CN100397082C (zh) 2008-06-25
FI981380L (fi) 1998-06-15
HU211905A9 (en) 1996-01-29
JP2810022B2 (ja) 1998-10-15
ES2012739T5 (es) 2001-12-01
CN1285514A (zh) 2001-02-28
CN1035679A (zh) 1989-09-20
EP0318216A1 (de) 1989-05-31
AU2796789A (en) 1989-06-14
JPH06128292A (ja) 1994-05-10
CN1049686C (zh) 2000-02-23
DE3886363T2 (de) 1994-05-19
FI20001390A7 (fi) 2000-06-12
IE62868B1 (en) 1995-03-08
CN1073719A (zh) 1993-06-30
NZ227011A (en) 1992-03-26
JP2810032B2 (ja) 1998-10-15
DE3886363T3 (de) 2004-09-09
CN1249433A (zh) 2000-04-05
NO892931D0 (no) 1989-07-17

Similar Documents

Publication Publication Date Title
EP0318216B1 (de) NANBV-Diagnostika und Vakzine
US5698390A (en) Hepatitis C immunoassays
US5350671A (en) HCV immunoassays employing C domain antigens
US6346375B1 (en) NANBV diagnostics and vaccines
JP3156200B2 (ja) 新規のhcv分離株
US6027729A (en) NANBV Diagnostics and vaccines
GB2212511A (en) Hepatitis C virus
DK175975B1 (da) NANBV-diagnostika og -vacciner
DK176280B1 (da) NANBV-diagnostika og -vacciner
AU624105C (en) NANBV diagnostics and vaccines
SI8812138A (sl) Nanbv diagnostiki in cepiva